A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT FOR THE TREATMENT OF URINARY INCONTINENCE IN SUBJECTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY OR MULTIPLE SCLEROSIS
- Registry ID
- D-FR-52120-222
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- IPSEN INNOVATION
- Start date
- 2016-07-29
- Last update
- 2016-03-11
Conditions
- NEUROGENIC DETRUSOR OVERACTIVITY
- MULTIPLE SCLEROSIS
Related clinical trials
- A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF REMIBRUTINIB IN PATIENTS WITH SECONDARY PROGRESSIVE
MULTIPLE SCLEROSIS
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, FOUR-ARM, PLACEBO-CONTROLLED, MULTICENTER STUDY ASSESSING THE EFFICACY, SAFETY AND TOLERABILITY OF THREE DOSES OF ORALLY ADMINISTERED BMS- 986368, A FAAH/MAGL INHIBITOR, FOR THE TREATMENT OF SPASTICITY IN PARTICIPANTS WITH MULTIPLE SCLEROSIS (BALANCE-MSS-1)
- THE DIFFERENTIAL EFFECTS OF THC VS. CBD ON COGNITION IN PERSONS WITH MS
- A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, NON-INFERIORITY STUDY COMPARING
EFFICACY, SAFETY, AND TOLERABILITY OF REMIBRUTINIB AFTER SWITCHING FROM
OCRELIZUMAB IN PARTICIPANTS LIVING WITH RELAPSING MULTIPLE SCLEROSIS, FOLLOWED BY
OPEN-LABEL TREATMENT WITH REMIBRUTINIB
- A PHASE 2, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING
STUDY OF MRNA-1195 INTRAMUSCULAR INJECTION IN PARTICIPANTS 18 TO ¿55
YEARS OF AGE WITH EARLY MULTIPLE SCLEROSIS
View on source registry